Treatment Approach for ADHD with Comorbid Anxiety

Initial Treatment Strategy

• The American Academy of Child and Adolescent Psychiatry recommends initiating a trial of stimulants as first-line treatment for ADHD, even in the presence of comorbid anxiety, as they improve both ADHD symptoms and reduce anxious symptoms in most cases 1, 2
• Stimulants offer a rapid onset of action, allowing for quick assessment of efficacy on ADHD symptoms 1, 2
• Methylphenidate and lisdexamfétamine have significant effect sizes for reducing core ADHD symptoms 3

Formulations and Dosage

• Prefer extended-release formulations to achieve "all-day" effects and minimize symptom rebound in the late afternoon/evening 3
• Different methylphenidate formulations allow for individualization of treatment according to the patient's daily needs 3

Sequential Decision Algorithm

Step 1: Evaluation After Stimulant Trial

• If both ADHD and anxiety symptoms improve, continue the stimulant alone without modification 1, 2
• No additional treatment is necessary 1, 2

Step 2: If Anxiety Remains Problematic Despite CBT

• Add an SSRI to the stimulant for residual anxiety 1, 4
• This combination is generally well-tolerated with appropriate precautions 1

Alternative Option: Atomoxetine

When to Consider Atomoxetine as First-Line

• Atomoxetine represents a suitable first-line alternative in specific contexts, such as severe anxiety, substance use disorders, or pre-existing sleep disorders 5, 6
• Atomoxetine offers "around-the-clock" effects without rebound 3, 5

Adjuvant Treatment with Alpha-2 Agonists

• If response is insufficient with stimulants or atomoxetine, consider guanfacine or clonidine as adjuvant treatment 3, 5, 6
• These agents treat both ADHD symptoms and emotional dysregulation 6

Necessary Surveillance

• Monitor height, weight, blood pressure, and pulse under stimulant treatment 3
• Monitor appetite and weight under atomoxetine 3, 6
• Monitor for suicidality under atomoxetine (black box warning) 3

Considerations by Severity

If Anxiety is the Primary Disorder with Severe Symptoms

• Treat anxiety first if it presents with very severe symptoms (major avoidance, significant distress) 1, 2
• Once anxiety is stabilized, re-evaluate ADHD symptoms and initiate appropriate treatment 6

Treatment of ADHD with Comorbid Anxiety

Primary Treatment Algorithm

• The American Academy of Pediatrics recommends that combined treatment, including stimulant plus behavior therapy, offers superior outcomes when ADHD coexists with anxiety, with improvements in academic performance and conduct measures beyond medication alone 7
• Titration of stimulant doses to achieve maximum benefit with minimum adverse effects is recommended, rather than using strict mg/kg dosing, with more than 70% of children responding optimally when systematic titration is employed 7, 8

Adjunctive Treatment Options

• Behavioral interventions, including behavior therapy programs across home and school settings, can enhance medication effects and allow for lower stimulant doses, potentially reducing adverse effects 7
• School accommodations, such as preferred seating, modified assignments, and test modifications, can be beneficial for children with ADHD and comorbid anxiety 7

Treatment Sequencing Based on Severity

• Treating ADHD may resolve the comorbid anxiety condition without additional intervention, with treatment of ADHD leading to improvement in coexisting anxiety symptoms in many cases 7, 8, 9

Common Pitfalls and How to Avoid Them

• Inadequate dosing and monitoring can lead to suboptimal outcomes, with systematic titration protocols recommended to avoid calculating doses strictly on mg/kg basis 7, 8
• Treating only one condition, either ADHD or the comorbid condition, can be insufficient, with primary care clinicians recommended to refer to subspecialists for severe mood or anxiety disorders requiring co-management 7, 8, 9

Treatment of Comorbid ADHD and Anxiety with Bupropion

Introduction to Bupropion for ADHD with Anxiety

• The American Academy of Child and Adolescent Psychiatry suggests that stimulants offer rapid onset, allowing quick assessment of whether ADHD symptoms—and often anxiety symptoms—have remitted, whereas bupropion requires weeks to months for full effect 10
• The American Academy of Child and Adolescent Psychiatry indicates that early concerns about stimulants worsening anxiety have been disproven: The MTA study and subsequent trials show that ADHD patients with comorbid anxiety actually have better treatment responses to stimulants than those without anxiety 10
• Bupropion is explicitly labeled as a second-line agent at best for ADHD treatment, with limited evidence supporting its use in this population, according to the American Academy of Child and Adolescent Psychiatry 10

Clinical Contexts for Bupropion Use

• In cases of active substance use disorder, bupropion avoids the abuse potential of stimulants while still addressing ADHD symptoms, as noted in Pharmacology and Therapeutics 11
• When stimulant non-response or intolerance occurs, bupropion can be considered as an alternative, according to Pharmacology and Therapeutics 11

Safety and Efficacy Considerations

• There is no evidence on combining bupropion with stimulants, and this combination should be approached with caution, as stated by the American Academy of Child and Adolescent Psychiatry 12
• The American Academy of Child and Adolescent Psychiatry recommends against assuming anxiety is a contraindication to stimulants, as this outdated belief deprives patients of the most effective treatment 10
• The American Academy of Child and Adolescent Psychiatry advises against using bupropion as first-line when stimulants are appropriate, as this chooses a less effective option with slower onset 10
• The American Academy of Child and Adolescent Psychiatry cautions against combining bupropion with stimulants without careful consideration, due to the lack of safety data for this combination 12

Treatment of ADHD with Comorbid Anxiety

Primary Treatment Algorithm

• The American Academy of Child and Adolescent Psychiatry recommends considering adding cognitive behavioral therapy (CBT) to the medication regimen if ADHD improves but anxiety remains problematic despite adequate SSRI dosing, as combination treatment (CBT plus SSRI) shows superior outcomes for anxiety disorders 13, 14
• Ensure the SSRI is at an adequate therapeutic dose before adding ADHD medications, as SSRIs can take 3-4 weeks to reach full effect, and be aware that SSRIs can initially cause anxiety or agitation as an adverse effect 13, 14

SSRI Management Considerations

• The American Academy of Child and Adolescent Psychiatry suggests that citalopram/escitalopram have the least effect on CYP450 enzymes and lower propensity for drug interactions with stimulants 13, 15
• Fluoxetine, paroxetine, and sertraline may interact with drugs metabolized by CYP2D6, and if using atomoxetine with an SSRI that is a strong CYP2D6 inhibitor, dose adjustment of atomoxetine may be necessary 13, 15

Adjuvant Treatment Options

• The American Academy of Child and Adolescent Psychiatry recommends adding CBT if anxiety remains problematic after optimizing medications, as combination treatment (CBT plus SSRI) shows superior outcomes for anxiety disorders including improved global function, response to treatment, and remission rates 13, 14
• CBT plus sertraline specifically showed moderate strength of evidence for improving anxiety symptoms in children and adolescents 13, 14

Monitoring Requirements

• The American Academy of Child and Adolescent Psychiatry suggests monitoring for suicidal ideation, clinical worsening, and unusual changes in behavior, particularly in children and adolescents when using SSRIs 13, 14

Treatment of ADHD and Anxiety with Psychostimulants and SSRIs

Initiation and Monitoring of Treatment

• The American Academy of Child and Adolescent Psychiatry recommends adding sertraline or fluoxetine to the optimized stimulant regimen if anxiety persists, starting with subtherapeutic "test" doses initially, as an adverse effect of SSRIs can be anxiety or agitation, and titrating shorter half-life SSRIs at 1-2 week intervals; longer half-life SSRIs at 3-4 week intervals 16
• The American Academy of Child and Adolescent Psychiatry suggests that starting both medications simultaneously prevents determining which medication is responsible for therapeutic effects or adverse effects, and that stimulants provide rapid symptom relief, allowing quick assessment of whether anxiety improves secondarily to ADHD treatment before committing to long-term SSRI therapy 16
• The American Academy of Child and Adolescent Psychiatry advises monitoring for suicidal ideation, clinical worsening, and unusual behavioral changes, particularly when initiating SSRIs in children and adolescents, and assessing for initial SSRI-induced anxiety or agitation, which typically emerges in the first 1-2 weeks 16
• The American Academy of Child and Adolescent Psychiatry recommends using standardized symptom rating scales to systematically assess treatment response for both ADHD and anxiety, and adding CBT to the medication regimen if anxiety remains problematic despite adequate SSRI dosing, as combination treatment shows superior outcomes compared to medication alone 16